Truvada

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

HIV InfectionHepatitis CTuberculosisImmunodeficiencyAdverse Effect

326 competitors in HIV Infection

#DrugCompanyPhaseTrials

1

Leukine

Sanofi

Phase 3

22

Truvada

Gilead

Approved

43

Sunlenca

Gilead

Phase 3

14

Betaseron

Bayer

Phase 3

—5

PEG-Intron

Merck & Co.

Phase 3

—6

Megace

Bristol-Myers Squibb

Phase 3

—7

Isentress

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

38

Foscavir

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 3

19

F/TDF

Gilead

Phase 3

110

PTM SEMA

Gilead

Phase 3

1Show 35 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prevention5 trials

Uptake and Adherence to Daily Oral PrEP as a Primary Prevention Strategy for Young African Women: A Vanguard Study

Completed·HHIV Prevention Trials Network·Phase 4·NCT02732730·451 enrolled

3Ps for Prevention Study (Perception, Partners, Pills)

Unknown status·DDesmond Tutu HIV Centre·Phase 4·NCT03142256·200 enrolled

SCOPE: Strategies to Combine PrEP With Prevention Efforts

Withdrawn·FFHI 360·N/A·NCT01832571

Show 2 more trials

The Prevention Options for Women Evaluation Research (POWER) Cohort

Completed·UUniversity of Washington··NCT03490058·2,255 enrolled

Introducing PrEP Into HIV Combination Prevention - Kenya

Unknown status·LLVCT Health·N/A·NCT02755350·2,100 enrolled

HIV infection4 trials

Safety Study of Isentress® + Truvada® in Post-exposure Treatment of HIV Infection

Completed·GGroupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux·Phase 3·NCT01114425·149 enrolled

Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection

Completed·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT00959894·80 enrolled

Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection Status

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT01040091·34 enrolled

Show 1 more trial

On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men

Completed·AANRS, Emerging Infectious Diseases·Phase 3·NCT01473472·400 enrolled

Pre-Exposure Prophylaxis (PrEP)3 trials

PrEPared-RN, CAN Nurse-Led Management of High-risk Patients for Pre-Exposure Prophylaxis (PrEP)

Unknown status·CCAN Community Health··NCT06030557·210 enrolled

Pre-Exposure Prophylaxis (PrEP) Adherence Monitoring Using Dried Blood Spots

Completed·UUniversity of Colorado, Denver·Phase 1/2·NCT02022657·52 enrolled

Demonstrating Safety and Effective Delivery of Daily Oral Pre-exposure Prophylaxis (PrEP) for Sex Workers in India

Completed·UUniversity of Manitoba·Phase 1·NCT02148094·1,325 enrolled

TED3 trials

Dual Therapy With Boosted Darunavir + Dolutegravir

Completed·TTechnical University of Munich·Phase 3·NCT02486133·269 enrolled

Boosted Atazanavir and Truvada Given Once-Daily - BATON Study

Completed·Gilead·Phase 4·NCT00224445·100 enrolled

Comparative Study of PK and BE of VM-1500FDC (Fixed-dose Combination) and Elpida® With Truvada® сo-administrated 1 Daily Fasting in Healthy Subjects

Completed·VViriom·Phase 1·NCT03706924·140 enrolled

Tenofovir3 trials

Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients

Completed·Gilead·Phase 4·NCT00106379·52 enrolled

Tenofovir Adherence to Rapidly Guide and Evaluate PrEP and HIV Therapy

Completed·UUniversity of Washington·N/A·NCT03012607·30 enrolled

Exploratory Pharmacodynamic Study of Tenofovir-Based Products

Completed·CCONRAD·Phase 1·NCT02722343·25 enrolled

30 more indications

PrEP2 trials

PrEPsmart 2-1-1 Pilot

Recruiting·PPublic Health Foundation Enterprises, Inc.·Phase 2·NCT06631365·60 enrolled

PrEP, Lube, and the Rectal Mucosa in MSM at Risk of HIV

Completed·EEmory University·Phase 4·NCT02401230·86 enrolled

Substance Use2 trials

Feasibility and Acceptability of Digital Pills to Monitor PrEP Adherence in MSM With Substance Use

Completed·—·Phase 4·NCT03842436·16 enrolled

Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps)

Completed·—·Phase 3·NCT03512418·30 enrolled

Prophylaxis2 trials

Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)

Completed·TThe University of Texas Health Science Center, Houston·Phase 4·NCT01214759·103 enrolled

Pre-Exposure Prophylaxis and Timed Intercourse for HIV-Discordant Couples

Withdrawn·UUniversity of Missouri-Columbia·N/A·NCT02572505

HIV Prevention2 trials

Reversing the Epidemic in Africa With Choices in HIV Prevention (REACH)

Withdrawn·IInternational Partnership for Microbicides, Inc.·Phase 2·NCT03074786

Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women

Completed·UUniversity of KwaZulu·Phase 2/3·NCT03227731·540 enrolled

Treatment2 trials

Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals

Terminated·GGeorge Washington University·Phase 4·NCT00632970·6 enrolled

SONETT: Switch Study to Once Daily HIV Treatment Regimen With Truvada

Completed·Gilead·Phase 4·NCT00323687·50 enrolled

Immunodeficiency2 trials

A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)

Completed·Merck & Co.·Phase 2·NCT01632345·342 enrolled

Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)

Completed·Merck & Co.·Phase 3·NCT02131233·802 enrolled

Oral1 trial

Biobehavioral Interventions for HIV-negative, Stimulant Using Men Who Have Sex With Men

Completed·FFriends Research Institute, Inc.·Phase 2·NCT01140880·170 enrolled

Female1 trial

Demonstration Project of PrEP Among Female Sex Workers in Dakar, Senegal

Completed·RRéseau Africain de Recherche sur le SIDA·N/A·NCT02474303·267 enrolled

Interaction1 trial

Pharmacokinetic Interaction Between TRUVADA™ and BILR 355 BS Plus Ritonavir in Healthy Volunteers

Completed·Boehringer Ingelheim·Phase 1·NCT02253901·33 enrolled

HIV Pre-Exposure Prophylaxis1 trial

Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities

Completed·EEmory University·Phase 1·NCT02985996·48 enrolled

Pregnancy1 trial

Randomized, Open Label Safety Trial of Dapivirine Vaginal Ring and Oral TRUVADA® Use in Pregnancy

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT03965923·1,104 enrolled

Tolerance1 trial

Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients

Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 2/3·NCT00391638·56 enrolled

HIV-11 trial

A Study Exploring an Induction-Maintenance Kaletra-Based Therapy Versus a Sustiva-Based Regimen in Previously Non-Treated, HIV-1/HCV Co-Infected Subjects

Withdrawn·AAbbott·Phase 2·NCT00121017·200 enrolled

Breastfeeding1 trial

Safety and Drug Detection Study of Dapivirine Vaginal Ring and Oral TRUVADA® in Breastfeeding Mother-Infant Pairs

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT04140266·394 enrolled

Adverse Effect1 trial

Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection

Completed·UUniversity of Cincinnati·Phase 4·NCT00885664·60 enrolled

Epstein Barr Virus1 trial

Effects of Antiviral Therapies on Epstein-Barr Virus Replication

Enrolling by invitation·MMassachusetts General Hospital·Phase 2·NCT05957913·50 enrolled

Dyslipidemia1 trial

Trial To Assess The Lipid-Lowering Effect Of Adding Tenofovir/Emtricitabine Co-Formulation Vs Placebo To Hiv-1-Infected Subjects With Dyslipidemia And Sustained Viral Load Suppression Under Monotherapy With Ritonavir-Boosted Protease Inhibitors

Completed·FFundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia·Phase 4·NCT01458977·48 enrolled

Gastrointestinal1 trial

Effects of the Anti-HIV Pill Truvada on Gene Transcription in the Gastrointestinal Tract of HIV-uninfected Individuals

Completed·UUniversity of Washington··NCT02621242·9 enrolled

Acceptability1 trial

Acceptability, Safety, and Use of Daily Truvada Pre-Exposure Prophylaxis in Adolescents

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT02213328·148 enrolled

First-line1 trial

ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy

Completed·PProfessor Francois Venter·Phase 3·NCT03122262·1,110 enrolled

High Risk1 trial

The Role of Home Packs of HIV PEPSE in High Risk Individuals

Completed·GGuy's and St Thomas' NHS Foundation Trust·Phase 4·NCT04965662·139 enrolled

Mitochondria1 trial

Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects

Completed·SSt. Luke's-Roosevelt Hospital Center·Phase 4·NCT00960622·17 enrolled

Hepatitis C1 trial

Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP

Completed·—·N/A·NCT05108935·17 enrolled

Methamphetamine1 trial

Contingency Management for Methamphetamine Abstinence and HIV Post-Exposure Prophylaxis in Men Who Have Sex With Men

Completed·FFriends Research Institute, Inc.·Phase 2·NCT00856323·53 enrolled

Women1 trial

FEM-PrEP (Truvada®): Study to Assess the Role of Truvada® in Preventing HIV Acquisition in Women

Completed·FFHI 360·Phase 3·NCT00625404·2,120 enrolled

Tuberculosis1 trial

REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 4·NCT01380080·851 enrolled

Safety and Efficacy1 trial

A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)

Terminated·Merck & Co.·Phase 3·NCT00745823·775 enrolled

CLE1 trial

TOTEM: Switch From Other Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to Once Daily Truvada

Completed·Gilead·Phase 4·NCT00323492·92 enrolled

Itching1 trial

Peripheral Body Fat Distribution After Switching Zidovudine and Lamivudine to Truvada

Completed·Gilead·Phase 4·NCT00324649·80 enrolled

Unspecified3 trials

Dolutegravir in Reservoirs

Terminated·EEmory University·Phase 4·NCT02924389·22 enrolled

Combination of Efavirenz and Truvada - COMET Study

Completed·Gilead·Phase 4·NCT00224458·400 enrolled

The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic Study

Completed·IImperial College London·Phase 1·NCT01348763·13 enrolled

Details

Drug Info

Related News